{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:50:23Z","timestamp":1791399023920,"version":"4.3.3"},"reference-count":36,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,6,13]]},"DOI":"10.18632\/oncotarget.17000","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T15:40:17Z","timestamp":1491838817000},"page":"39356-39366","source":"Crossref","is-referenced-by-count":25,"title":["Simultaneous exposure to Fc\u03b3R and Fc\u03b1R on monocytes and macrophages enhances antitumor activity<i>in vivo<\/i>"],"prefix":"10.18632","volume":"8","author":[{"given":"Bingyu","family":"Li","sequence":"first","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tao","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Pi","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mendelsohn","sequence":"additional","affiliation":[{"name":"Panorama Research Institute, Sunnyvale, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Larrick","sequence":"additional","affiliation":[{"name":"Panorama Research Institute, Sunnyvale, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Gu","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Fang","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Technology, Tongji University, Shanghai, China"},{"name":"Shanghai Tongji Hospital, Tongji University, Shanghai, China"},{"name":"Tongji University Suzhou Institute, Suzhou, China"},{"name":"Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,4,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Seminars in hematology"},{"key":"3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Rose","year":"2002","journal-title":"Anti-cancer drugs"},{"key":"4","first-page":"7170","article-title":"Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways","volume":"60","author":"Mapara","year":"2000","journal-title":"Cancer research"},{"key":"5","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Mitsiades","year":"2007","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Old","year":"2012","journal-title":"Nature reviews Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1126\/science.288.5474.2222","article-title":"A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria","volume":"288","author":"Zinkernagel","year":"2000","journal-title":"Science"},{"key":"8","first-page":"217","article-title":"CD89: the human myeloid IgA Fc receptor","volume":"49","author":"Brandtzaeg","year":"2001","journal-title":"Archivum immunologiae et therapiae experimentalis"},{"key":"9","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4049\/jimmunol.0902033","article-title":"A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells","volume":"184","author":"Stockmeyer","year":"2010","journal-title":"Journal of immunology"},{"key":"10","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.4049\/jimmunol.179.5.2936","article-title":"Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor","volume":"179","author":"Valerius","year":"2007","journal-title":"Journal of immunology"},{"key":"11","doi-asserted-by":"crossref","first-page":"25139","DOI":"10.1074\/jbc.M112.353060","article-title":"Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages","volume":"287","author":"Valerius","year":"2012","journal-title":"The Journal of biological chemistry"},{"key":"12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/emmm.201201929","article-title":"IgA EGFR antibodies mediate tumour killing in vivo","volume":"5","author":"Parren","year":"2013","journal-title":"EMBO molecular medicine"},{"key":"13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/19420862.2015.1047570","article-title":"Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcalphaRI (CD89) binding","volume":"7","author":"Tsui","year":"2015","journal-title":"mAbs"},{"key":"14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Tedder","year":"2004","journal-title":"The Journal of experimental medicine"},{"key":"15","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ijc.26457","article-title":"Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients","volume":"131","author":"Jalkanen","year":"2012","journal-title":"International journal of cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","article-title":"M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro","volume":"182","author":"Golay","year":"2009","journal-title":"Journal of immunology"},{"key":"17","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.chembiol.2014.10.017","article-title":"IgGA: a \u201ccross-isotype\u201d engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions","volume":"21","author":"Georgiou","year":"2014","journal-title":"Chemistry & biology"},{"key":"18","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2008-03-144600","article-title":"Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells","volume":"112","author":"Valerius","year":"2008","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"e0159426","DOI":"10.1371\/journal.pone.0159426","article-title":"Critical Role of Kupffer Cell CD89 Expression in Experimental IgA Nephropathy","volume":"11","author":"Fang","year":"2016","journal-title":"PloS one"},{"key":"20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.immuni.2011.11.009","article-title":"Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo","volume":"35","author":"Nimmerjahn","year":"2011","journal-title":"Immunity"},{"key":"21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0165-2478(99)00034-6","article-title":"The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis","volume":"68","author":"van de Winkel","year":"1999","journal-title":"Immunology letters"},{"key":"22","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Quezada","year":"2013","journal-title":"The Journal of experimental medicine"},{"key":"23","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.4049\/jimmunol.164.11.5746","article-title":"Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages","volume":"164","author":"Deo","year":"2000","journal-title":"Journal of immunology"},{"key":"24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.immunol.21.120601.141011","article-title":"IgA Fc receptors","volume":"21","author":"Van De Winkel","year":"2003","journal-title":"Annual review of immunology"},{"key":"25","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Anderson","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"26","first-page":"161","article-title":"Hepatic and kidney uptake of soluble monomeric and polymeric IgA aggregates","volume":"52","author":"Egido","year":"1984","journal-title":"Immunology"},{"key":"27","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.2011.047159","article-title":"The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden","volume":"96","author":"Leusen","year":"2011","journal-title":"Haematologica"},{"key":"28","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-09-4109","article-title":"In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling","volume":"70","author":"Leusen","year":"2010","journal-title":"Cancer research"},{"key":"29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Ravetch","year":"2000","journal-title":"Nature medicine"},{"key":"30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1084\/jem.20052283","article-title":"Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy","volume":"203","author":"Tedder","year":"2006","journal-title":"The Journal of experimental medicine"},{"key":"31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/clim.2001.5083","article-title":"Hybrid IgA2\/IgG1 antibodies with tailor-made effector functions","volume":"101","author":"Morrison","year":"2001","journal-title":"Clinical immunology"},{"key":"32","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.4049\/jimmunol.130.4.1826","article-title":"Clearance kinetics and fate of mouse IgA immune complexes prepared with monomeric or dimeric IgA","volume":"130","author":"Mannik","year":"1983","journal-title":"Journal of immunology"},{"key":"33","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Vonderheide","year":"2011","journal-title":"Science"},{"key":"34","article-title":"Bone Marrow-Derived Macrophages BMM: Isolation and Applications","volume":"2008","author":"Porse","year":"2008","journal-title":"CSH protocols"},{"key":"35","doi-asserted-by":"crossref","first-page":"15712","DOI":"10.1038\/srep15712","article-title":"Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity","volume":"5","author":"Li","year":"2015","journal-title":"Scientific reports"},{"key":"36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/19420862.2015.1106658","article-title":"Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting","volume":"8","author":"Leusen","year":"2016","journal-title":"mAbs"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:35:41Z","timestamp":1692758141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,10]]},"references-count":36,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,6,13]]}},"alternative-id":["17000","28454118"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17000","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,10]]}}}